5.76
-29.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zivo Bioscience
From its filings with the US Securities and Exchange Commission
Zivo Bioscience is based in Bloomfield Hills, Michigan and is incorporated in Nevada. Its shares trade on OTC under the ticker ZIVO. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2024, it reported revenue of $157,220 and a net loss of $13.4m. At that date it held total assets of $1.6m and shareholders' equity of −$514,897.
We are a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health.
We believe that our proprietary algal culture and materials derived therefrom show promise in benefiting both animal and human health, primarily through inflammation-modulating and immune-boosting properties. Overall, our efforts have been centered around two potential value-creating initiatives; the first being the identification of bioactive extracts or novel bioactive molecules from our proprietary algal culture to treat various diseases, and second, the utilization of our proprietary algal culture in its whole form as a food product to leverage its nutritional value. In the first quarter of 2022, we reformulated our biotech and agtech businesses around these two concepts. We reviewed the market potential (scale and profit) and the technical and business risks associated with each of the opportunities we had been working on and developed a focused strategy for each business.
Quoted from its 10-K, filed 18 Mar 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Products
- Listed since
- 6 Oct 2000
- Employees
- 8
- Website
- zivobioscience.com ↗
- Head office
- 21 E. LONG LAKE ROAD, BLOOMFIELD HILLS, MI, 48304
- Incorporated in
- NV
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John PayneChairman of the Board, President, Chief Executive Office, Director, since 2013$738,819
- Mr. Keith MarchiandoChief Financial Officer$324,480
- Ms. Alison CornellIndependent Director$1.7m
- Mr. Christopher MaggioreIndependent Director$1.0m
- Mr. Laith YaldooIndependent Director$23,356
- Mr. Tirth PatelInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zivo Bioscience develops natural bioactive molecules from proprietary algal strains for human and animal health markets.
- The company focuses on research and identification of bioactive ingredients for dietary supplements and medical foods.
- Zivo Bioscience has a product platform for algal-derived compounds used in pharmaceutical applications.
Weaknesses
- Zivo Bioscience employs only 8 full-time employees, limiting operational capacity.
- The company went public in 2000, indicating limited growth since IPO.
- Zivo Bioscience's business is concentrated in natural nutritional compounds with narrow market focus.
Opportunities
- Zivo Bioscience can expand its algal product platforms into new markets like medical foods and supplements.
- The growing demand for natural health products presents opportunities for Zivo Bioscience's bioactive molecules.
- Zivo Bioscience may develop new applications for its algal strains in autoimmune and inflammatory response modulation.
Threats
- Zivo Bioscience faces competition from other natural compound developers in the Consumer Staples sector.
- The company's reliance on algal strains could be threatened by environmental or regulatory changes.
- Zivo Bioscience's small employee count may hinder its ability to respond to market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.